Black Hills Cardiovascular Research

Rapid City, South Dakota 57701

0 studies enrolling now · 15 studies all time

What they study most

Acute Coronary Syndrome, Acute Myocardial Infarction, Atrial Fibrillation, Cardiovascular Diseases, Coronary Artery Disease, Diabetes Mellitus, Type 2, Heart Failure, High Bleeding Risk, Left Ventricular Dysfunction, Lower Extremity Arterial Disease, Paroxysmal Supraventricular Tachycardia, Paroxysmal Supraventricular Tachycardia (PSVT)

Studies at this site

• A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation — Running, not enrolling
• TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure — Completed
• PRE-DETERMINE Cohort Study — Running, not enrolling
• A 12 Month Site Randomized Trial in Adults With Type 2 Diabetes Mellitus and History of Cardiovascular Disease — Completed
• Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302 — Stopped early
• Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF) — Completed
• GLORIA-AF Registry Program - Second and Third Phases — Completed
• LEADERS FREE II: BioFreedom™ Pivotal Study — Running, not enrolling
• Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm — Completed
• This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms. — Completed
• This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms — Completed
• EverFlex Post Approval Study — Completed
• Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease — Completed
• A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI — Stopped early
• A Study of INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention — Completed